SCHEMBL424971

SCHEMBL424971

CCCCSc1ccc(C)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.56
MAOA P21397 1/20 0.55
MAOB P27338 1/20 0.55
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
HTT P42858 2/20 0.49
TSHR P16473 1/20 0.49
MEN1 O00255 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
KMT2A Q03164 1/20 0.49
POLB P06746 1/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SLC2A1 P11166 1/20 0.46
AR P10275 1/20 0.44
DRD2 P14416 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5683064 0.93 HPGD (0.54) HPGDMAOAMAOBNPC1RAB9A
SCHEMBL6304397 0.91 HPGD (0.53) HPGDMAOAMAOBNPC1RAB9A
SCHEMBL5316777 0.91 HPGD (0.53) HPGDMAOAMAOBNPC1RAB9A
SCHEMBL9491957 0.91 HPGD (0.53) HPGDMAOAMAOBNPC1RAB9A
SCHEMBL9745598 0.91 HPGD (0.53) HPGDMAOAMAOBNPC1RAB9A
SCHEMBL5887468 0.91 MAOA (0.62) HPGDMAOAMAOBNPC1RAB9A
SCHEMBL12169764 0.90 HPGD (0.49) HPGDMAOAMAOBNPC1RAB9A
SCHEMBL9808095 0.88 NPC1 (0.55) HPGDNPC1RAB9ACYP1A2CYP2C19
SCHEMBL5172043 0.88 POLB (0.56) HPGDNPC1RAB9ACYP1A2CYP2C19
SCHEMBL10528635 0.86 SLC2A1 (0.51) HPGDMAOAMAOBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO disclosed
CN-117945964-A Synthesis method of aryl alkyl asymmetric thioether 中国人民解放军军事科学院防化研究院 2024-04-30 CN disclosed
EP-4194477-A1 PHOTOCATIONIC CURABLE COMPOSITION AND CURABLE DENTAL COMPOSITION Tokuyama Dental Corporation (JP) 2023-06-14 EP disclosed
US-11192908-B2 Octamolybdate compounds exhibiting bright emission NANOCO 2D MATERIALS LIMITED (GB) 2021-12-07 US disclosed
EP-3837267-A1 POLYOXOMETALATE COMPOUNDS EXHIBITING BRIGHT EMISSION AND METHODS OF PRODUCING THE SAME Nanoco 2D Materials Limited (GB) 2021-06-23 EP disclosed
CN-112533934-A Polyoxometallate compounds exhibiting bright emission and methods of making the same 纳米2D材料有限公司 2021-03-19 CN disclosed
CN-107922622-B Siloxane crosslinking process using sulfur compounds and platinum catalysts 莫门蒂夫性能材料股份有限公司 2021-03-16 CN disclosed
EP-3301097-B1 [1]BENZOTHIENO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) SAMSUNG DISPLAY CO LTD (KR) 2020-08-19 EP disclosed
EP-3522244-B1 MICROCRYSTALLINE ORGANIC SEMICONDUCTOR FILM, ORGANIC SEMICONDUCTOR TRANSISTOR, AND METHOD FOR PRODUCING ORGANIC SEMICONDUCTOR TRANSISTOR FUJIFILM CORP (JP) 2020-07-15 EP disclosed
EP-3320026-B1 SILOXANE CROSSLINKING PROCESSES EMPLOYING SULFUR COMPOUNDS AND PLATINUM CATALYSTS MOMENTIVE PERFORMANCE MAT INC (US) 2020-03-04 EP disclosed
CN-101231464-A Photoacid generators, photoresist composition including the same and method of forming pattern using the same SAMSUNG ELECTRONICS CO LTD (KR) 2008-07-30 CN disclosed
EP-1803034-A2 HOLOGRAPHIC STORAGE MEDIUM General Electric Company (US) 2007-07-04 EP disclosed
EP-1195259-B1 Sheet for ink jet-recording OJI PAPER CO (JP) 2007-04-25 EP disclosed
WO-2006044243-A2 HOLOGRAPHIC STORAGE MEDIUM GENERAL ELECTRIC COMPANY A CORPORATION OF THE STATE OF NEW YORK (US) 2006-04-27 WO disclosed
US-6652930-B2 Comprises mixture of compounds such as 1,2-bis(2-hydroxyethyl thio)ethane and homo/copolymers of diallylamine compounds such as polydiallylamine hydrochloride; phthalocyanine dye adds to stability; discoloration inhibition extends shelf-life OJI PAPER CO., LTD. (JP) 2003-11-25 US disclosed
WO-2003007954-A2 SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2003-01-30 WO disclosed
US-20020071941-A1 Sheet for ink jet-recording OJI PAPER CO., LTD. (JP) 2002-06-13 US disclosed
EP-1195259-A2 Sheet for ink jet-recording OJI PAPER CO., LTD. (JP) 2002-04-10 EP disclosed
US-4338232-A Radiation-curable resins THE DOW CHEMICAL COMPANY (US) 1982-07-06 US disclosed
US-4020030-A CROSSLINKABLE THE DOW CHEMICAL COMPANY (US) 1977-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192908-B2 Octamolybdate compounds exhibiting bright emission KCNN4, PUF60, OCIAD1 HPGD 3635/4885MAOA 601/4885MAOB 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.